Correction: Van bruggen et al. Overcoming the hurdles of autologous T-cell-based therapies in B-cell non-hodgkin lymphoma (Cancers (2020), 12, (3837), 10.3390/cancers12123837)

Research output: Contribution to journalComment/Letter to the editorAcademic

Abstract

In the original article [1], reference [46] was not cited correctly in Table 1. The citation has now been inserted in Section 2.1. “Immune Checkpoint Blockade”, Table 1: the original citation “Zinzani et al., 2019” should read “Zinzani et al., 2019 [46]”. In the original article, reference [84] was not cited correctly in Table 3. The citation has now been inserted in Section 2.3. “Chimeric Antigen Receptor Therapy”, Table 3: the original citation “Fraietta et al., 2016 [78]” should read: “Fraietta et al., 2016 [84]”. The reference citation numbers from Section 3.2. “T-Cell Skewing”, paragraph two, line three onwards were incorrectly written as a result of four missing references in the reference section. They have been corrected after the references were reinserted with the following numbers: [103], [117], [153] and [192]: 103. Tinhofer, I.;Weiss, L.; Gassner, F.; Rubenzer, G.; Holler, C.; Greil, R. Difference in the relative distribution of CD4+ T-cell subsets in B-CLL with mutated and unmutated immunoglobulin (Ig) VH genes: implication for the course of disease. J. Immunother. 2009, 32, 302–309, doi:10.1097/CJI.0b013e318197b5e4. 117. Song, D.G.; Ye, Q.; Carpenito, C.; Poussin, M.; Wang, L.P.; Ji, C.; Figini, M.; June, C.H.; Coukos, G.; Powell, D.J., Jr. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011, 71, 4617–4627, doi:10.1158/0008-5472.CAN-11-0422. 153. Ramsay, A.G.; Johnson, A.J.; Lee, A.M.; Gorgun, G.; Le Dieu, R.; Blum, W.; Byrd, J.C.; Gribben, J.G. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Investig. 2008, 118, 2427–2437, doi:10.1172/JCI35017. 192. Ramsay, A.G.; Evans, R.; Kiaii, S.; Svensson, L.; Hogg, N.; Gribben, J.G. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood 2013, 121, 2704–2714, doi:10.1182/blood-2012-08-448332. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.
Original languageEnglish
Article number4738
JournalCancers
Volume13
Issue number19
DOIs
Publication statusPublished - 1 Oct 2021

Cite this